News Release

Women reveal the reasons they reject a preventive drug for breast cancer

Peer-Reviewed Publication

Cancer Research UK

Only around a fifth of women at higher risk of developing breast cancer think they need to take a drug proven to help prevent the disease, according to new research funded by Cancer Research UK and published today (Monday) in Clinical Breast Cancer.*

Around 72% said they were worried about the long-term effects of tamoxifen and 57% believed that the drug would give them unpleasant side-effects.

The researchers, led by a team from the University of Leeds, asked more than 400 healthy women at a higher-risk of breast cancer, from 20 centres across England, whether they thought they needed to take tamoxifen and their concerns about medication.

They discovered that almost a third (29%) of the women thought doctors prescribed too many medicines, and more than a third (35%) thought doctors would prescribe fewer drugs if they had more time. Around a quarter (24%) of the women had experienced bad reactions to medicines in the past.

Almost a quarter (24%) of the women thought people on medication should take regular breaks from the drugs; 23% said they were very sensitive to medicines and 17% believed natural remedies were safer than medicines.

In a follow-up questionnaire, answered by 250 of the women, researchers found that fewer than 15 per cent were taking tamoxifen** despite having discussed preventive therapy with a healthcare professional. Women who believed the medication was less necessary and had more concerns about its use were less likely to be taking tamoxifen at follow-up.

Lead author Dr Samuel Smith, from the University of Leeds, said: "Women in our study were rightfully considering the potential harms and benefits of using preventive therapy. But some beliefs about the use of medicine were very negative. This appears to be putting some women off tamoxifen, despite its proven ability to help prevent breast cancer in the long term.

"We need to make sure health care professionals are adequately equipped to discuss the potential benefits and harms of preventive treatment with their patients so that women are well informed before deciding whether or not to take a drug."

Dr Julie Sharp, Cancer Research UK's head of health information, said: "It's understandable that women considering taking a new medicine might have some concerns and that, for some, it won't be the right option. There are some potential side effects with tamoxifen, and other medications that can help prevent cancer, but it's vital that they have all the information, so they can make the best choice for them. If women in this situation have any questions or want more information, they can visit our website or call our cancer nurses for a chat. ***

###

Notes to editor

Increased risk is defined by NICE as a woman who has at least a 17% lifetime risk of being diagnosed with breast cancer.

*Thorneloe RJ, Horne R, Side L, Wolf MS, Smith SG, on behalf of the ENGAGE investigators, Beliefs about medication and uptake of preventive therapy in women at increased risk of breast cancer: Results from a multi-centre prospective study, Clinical Breast Cancer (2018), doi: https://doi.org/10.1016/j.clbc.2018.10.008

** Women were classified as initiating tamoxifen if they reported they were currently taking tamoxifen or if they had a prescription from their GP as some women may not have had the opportunity to collect their prescription and start the medication yet.

***Cancer Research UK Nurses freephone helpline 0808 800 4040


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.